Secondary acute myelogenous leukemia in patients with retinoblastoma. Is chemotherapy a factor? Journal Article

  

Authors:	Gombos, D. S.; Hungerford, J.; Abramson, D. H.; Kingston, J.; Chantada, G.; Dunkel, I. J.; Antoneli, C. B. G.; Greenwald, M.; Haik, B. G.; Leal, C. A.; Medina-Sanson, A.; Schefler, A. C.; Veerakul, G.; Wieland, R.; Bornfeld, N.; Wilson, M. W.; Yu, C. B. O.
Article Title:	Secondary acute myelogenous leukemia in patients with retinoblastoma. Is chemotherapy a factor?
Abstract:	Purpose: To describe a series of patients with secondary acute myelogenous leukemia (sAML) and retinoblastoma (RB). Design: Retrospective observational cases series. Participants: Ocular and pediatric oncologists at referral centers in Europe and the Americas and the RB databases at the National Institutes of Health and the Ophthalmic Oncology Service at Memorial Sloan-Kettering Cancer Center. Methods: Physician survey, retrospective database review, and literature search. Main Outcome Measures: History of RB and development of sAML, management of RB (surgery, radiotherapy, chemotherapy), age at diagnosis of RB and leukemia, French-American-British (FAB) subtype, and current status of patient (alive or dead). Results: Fifteen patients with sAML were identified; 13 occurred in childhood. Mean latent period from RB to AML diagnosis was 9.8 years (median, 42 months). Nine cases were of the M2 or M5 FAB subtypes. Twelve patients (79 %) had received chemotherapy with a topoisomerase II inhibitor, 8 (43%) had received chemotherapy with an epipodophyllotoxin. Ten children died of their leukemia. Conclusions: Acute myelogenous leukemia is a rare secondary malignancy among retinoblastoma patients, many of whom were treated with primary or adjuvant chemotherapy. Additional studies are needed to assess potential risk factors contributing to sAML development in this cohort. © 2007 American Academy of Ophthalmology.
Keywords:	cancer chemotherapy; child; clinical article; controlled study; child, preschool; leukemia; cancer surgery; retrospective studies; acute granulocytic leukemia; cisplatin; doxorubicin; cancer radiotherapy; cytarabine; methotrexate; disease association; carboplatin; multiple cycle treatment; cohort studies; etoposide; antineoplastic agents, phytogenic; cyclophosphamide; vincristine; retinoblastoma; retinal neoplasms; data base; ifosfamide; time factors; europe; infant; infant, newborn; enzyme inhibitors; newborn; age distribution; idarubicin; neoplasms, second primary; cyclosporin a; databases, factual; health care organization; patient referral; teniposide; dna topoisomerases, type ii; cryotherapy; gyrase inhibitor; podophyllotoxin; epipodophyllotoxin; leukemia, myelocytic, acute
Journal Title:	Ophthalmology
Volume:	114
Issue:	7
ISSN:	0161-6420
Publisher:	Elsevier Science, Inc.
Date Published:	2007-07-01
Start Page:	1378
End Page:	1383
Language:	English
DOI:	10.1016/j.ophtha.2007.03.074
PUBMED:	17613328
PROVIDER:	scopus
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-34347342867&partnerID=40&md5=a4da9076dea527afa1c3b266732afb5f
Notes:	--- - "Cited By (since 1996): 29" - "Export Date: 17 November 2011" - "CODEN: OPHTD" - "Source: Scopus"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/17407